Statera Biopharma, Inc.
staterabiopharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 14, 2022. Its latest SEC filing is a 25-NSE from Mar 3, 2023.
10-Q for Q3 FY2022, filed Nov 14, 2022
The sections below describe the company as of the FY2021 annual report.
What Did They Do?
Develops immune-based drug candidates for patients with immune disorders, infections and cancers, and provides preclinical research services to pharmaceutical developers.
10-K for FY2021, filed Oct 6, 2022We are a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use…View ↗
The Company is a discovery and developmental-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune…View ↗
On June 24, 2021, Old Cytocom completed the acquisition of ImQuest Life Sciences, Inc. and its subsidiaries ("ImQuest") in accordance with…View ↗
How Did They Make Money?
Customers pay a fixed fee for preclinical research projects; Statera is paid when it delivers the final report.
10-K for FY2021, filed Oct 6, 2022
$1.5M
-
10-K for FY2021, filed Oct 5, 2022
$1.5M ↗
Who Were Their Customers?
ImQuest provides preclinical research services to customers assessing pharmaceutical products; one ImQuest employee is devoted to marketing and sales of those services.
Did Revenues Turn Into Profits?
No. It lost $101.9M in FY2021.
10-K for FY2021, filed Oct 5, 2022
−$98.3MView ↗
10-K for FY2021, filed Oct 5, 2022
−$101.9MView ↗
10-K for FY2021, filed Oct 5, 2022
−$28.4MView ↗
How Were They Changing?
-
Jan 20, 2023
Nasdaq delisted the company's common stock
Trading moved to OTC Pink Open Market under STAB; the company said it planned to appeal.
Sources
8-K, filed Jan 20, 2023
As previously disclosed, on October 26, 2022, Statera Biopharma, Inc. (the “Company”) received a determination from a Nasdaq Hearings Panel…View ↗
Broader pipeline and research services
The older report centered on entolimod as a radiation countermeasure, while the latest describes a broader immunotherapy pipeline for immune disorders, infections and cancers, alongside ImQuest's preclinical research services.
10-K for FY2018, filed Mar 7, 2019 10-K for FY2021, filed Oct 6, 2022
Who Did They Compete With?
Competes with Amgen, Sanofi-Aventis, J&J, Partner therapeutics, Aeolus Pharmaceuticals, Araim Pharmaceuticals, Cellerant Therapeutics, Humanetics, Neumedicines, Pluristem Therapeutics, RxBio, and Soligenix
10-K for FY2021, filed Oct 6, 2022Companies that we are aware of with targeted immune-stimulating therapeutics in the treatment of autoimmune, neutropenia/anemia, emerging…View ↗
Loading...
